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Objectives: A neurophysiologic biomarker for autism spectrum disorder (ASD) is highly
desirable and can improve diagnosis, monitoring, and assessment of therapeutic
response among children with ASD. We investigated the utility of continuous theta-burst
stimulation (cTBS) applied to the motor cortex (M1) as a biomarker for children and
adolescents with high-functioning (HF) ASD compared to their age- and gender-matched
typically developing (TD) controls. We also compared the developmental trajectory of
long-term depression- (LTD-) like plasticity in the two groups. Finally, we explored the
influence of a common brain-derived neurotrophic factor (BDNF) polymorphism on cTBS
aftereffects in a subset of the ASD group.
Methods: Twenty-nine children and adolescents (age range 10–16) in ASD (n = 11)
and TD (n = 18) groups underwent M1 cTBS. Changes in MEP amplitude at 5–60 min
post-cTBS and their cumulative measures in each group were calculated. We also
assessed the relationship between age and maximum cTBS-induced MEP suppression
(∆MEPMax) in each group. Finally, we compared cTBS aftereffects in BDNF Val/Val (n = 4)
and Val/Met (n = 4) ASD participants.
Results: Cumulative cTBS aftereffects were significantly more facilitatory in the ASD
group than in the TD group (PFDR’s < 0.03). ∆MEPMax was negatively correlated with
age in the ASD group (r = −0.67, P = 0.025), but not in the TD group (r = −0.12,
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AMT, active motor threshold; BDNF, brain-derived
neurotrophic factor; cTBS, continuous theta-burst stimulation; ∆MEP, natural log-transformed, baseline-corrected
amplitude of motor evoked potentials; EEG, electroencephalography; EMG, electromyography; FDR, false discovery rate;
fMRI, functional magnetic resonance imaging; GABA, gamma-aminobutyric acid; HF, high-functioning; IQ, intelligence
quotient; iTBS, intermittent theta-burst stimulation; LF, low-functioning; LTD, long-term depression; LTP, long-term
potentiation; MEP, motor evoked potential; Met, metionine; PAS, paired associative stimulation; PCR, polymerase
chain reaction; RMT, resting motor threshold; rTMS, repetitive transcranial magnetic stimulation; SICI, short-interval
intracortical cortical inhibition; SNP, single-nucleotide polymorphism; TMS, transcranial magnetic stimulation; Tn, at n
minutes post-cTBS; Val, valine; %∆, percent change from the baseline.
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P = 0.65). Cumulative cTBS aftereffects were not significantly different between the two
BDNF subgroups (P-values > 0.18).
Conclusions: The results support the utility of cTBS measures of cortical plasticity as
a biomarker for children and adolescents with HF-ASD and an aberrant developmental
trajectory of LTD-like plasticity in ASD.
Keywords: transcranial magnetic stimulation, continuous theta-burst stimulation, plasticity, biomarker, autism
spectrum disorder, BDNF
INTRODUCTION
Autism spectrum disorder (ASD) is characterized by social
communication deficits and restricted, repetitive, and
stereotyped behaviors and interests (American Psychiatric
Association, 2013). Due to the large variability in the clinical
phenotype of ASD and manifestation of symptoms over a
range of ages in childhood, a clinical diagnosis of ASD can
be challenging and is often not made until 3–5 years of age.
For this reason, a neurophysiologic ASD biomarker is highly
desirable, particularly for improving diagnostic specificity
and for enabling metrics of therapeutic target-engagement
and outcomes.
Aberrant synaptic plasticity in patients with ASD can be
measured in vivo at the circuit level by transcranial magnetic
stimulation (TMS; Huang et al., 2005; Hallett, 2007; Pascual-
Leone et al., 2011). TMS enables focal noninvasive brain
stimulation by electromagnetic induction (Barker et al., 1985;
Kobayashi and Pascual-Leone, 2003; Hallett, 2007), to evoke or
modulate neural activity in a given brain region or network
(Valero-Cabré et al., 2017). When the recommended guidelines
are followed (Rossi et al., 2009; Rossini et al., 2015), TMS is
safe and well-tolerated, even in pediatric populations (Garvey
and Gilbert, 2004; Rajapakse and Kirton, 2013; Hameed
et al., 2017). TMS, when combined with electromyography
(EMG), electroencephalography (EEG), or neuroimaging such
as functional magnetic resonance imaging (fMRI) can quantify
the extent of modulation of cortical reactivity induced by an
intervention, providing an index of brain plasticity (Pascual-
Leone et al., 2011).
Patterned repetitive TMS (rTMS) protocols in humans
approximate experimental protocols that predictably induce
long-term depression (LTD) and long-term potentiation (LTP)
of synaptic strength in animal models (Huang et al., 2005, 2008).
A form of rTMS termed continuous theta-burst stimulation
(cTBS) consists of 50 Hz bursts of three TMS pulses repeated
at 5 Hz for a total of 600 pulses over 40 s (Huang et al.,
2005). Following cTBS of the primary motor cortex (M1), the
average amplitude of motor evoked potentials (MEPs) induced
by single TMS pulses is typically reduced by 25% for up to
50 min, before returning to pre-cTBS baseline (Wischnewski
and Schutter, 2015). The cTBS-induced neuromodulatory effect
has LTD-like characteristics (Cárdenas-Morales et al., 2011)
and involves mechanisms of GABAergic and glutamatergic
plasticity (Stagg et al., 2009; Trippe et al., 2009; Benali et al.,
2011). Thus, cTBS aftereffects provide a neurophysiologic
index of the mechanism of LTD-like cortical plasticity that is
abnormal in patients with ASD (Pascual-Leone et al., 2005, 2011;
Oberman et al., 2010).
Pursuant to cTBS (Oberman et al., 2012), adults with
high-functioning (HF) ASD have greater and longer-lasting
MEP suppression as compared to neurotypical (NT) controls,
indicating an exaggerated, hyperplastic, response to patterned
cortical stimulation. Additionally (Oberman et al., 2014), cTBS
measures of plasticity among children and adolescents with
HF-ASD demonstrate a positive linear relationship between age
and the extent of cTBS-induced modulation. These findings
reveal an age-related increase in LTD-like plasticity in childhood
and adolescence.
We now extend the scope of previous cTBS studies in
10–16 years old children with high-functioning ASD addressing
two questions: (1) are cTBS aftereffects different between
ASD and typically developing (TD) groups? (i.e., is the cTBS
biomarker adequate to distinguish children and adolescents
with HF-ASD from age-matched TD controls?); and (2) does
the developmental trajectory of cortical plasticity, as measured
by cTBS aftereffects, differ between the two groups? (i.e., is
there cortical dysmaturity in children with HF-ASD associated
with delayed or aberrant maturation of LTD-like plasticity
as measured by cTBS?). We also conduct pilot analysis on
a subset of the ASD group, to test whether cTBS measures
of plasticity were affected by a common single-nucleotide
polymorphism (SNP) in the brain-derived neurotrophic factor
(BDNF) gene, Val66Met, which has influences on rTMS
measures of cortical plasticity in healthy subjects (Cheeran et al.,
2008; Antal et al., 2010; Lee et al., 2013; Chang et al., 2014;
Di Lazzaro et al., 2015; Fried et al., 2017; Jannati et al., 2017;
Jannati et al., 2019).
MATERIALS AND METHODS
Participants
Twenty-nine individuals participated in this study, which
was approved by the local Institutional Review Board in
accordance with the Declaration of Helsinki. All participants
or their parents/legal guardians provided written informed
consent/assent prior to enrollment and received age-appropriate
monetary compensation in the form of a gift card upon
completion. No participants endorsed TMS-specific
contraindications (Rossi et al., 2009), and neurological
examination was unremarkable for all participants enrolled.
The two study populations were as follows: (1) high-functioning
children with idiopathic ASD (n = 11; ASD group); and
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(2) neurotypical age- and gender-matched controls (n = 18;
TD group). The TD group were originally recruited as
part of a separate and unrelated study, and not for the
purpose of comparing cTBS responses between TD and
ASD children. Participants were recruited through local
community advertisements, and local autism associations
and clinics. All participants in the ASD group carried a
prior clinical diagnosis made by a psychiatrist or clinical
psychologist, met diagnostic criteria for ASD as defined by
the Diagnostic and Statistical Manual of Mental Disorders, 5th
edition (DSM-5©; American Psychiatric Association, 2013),
and underwent independent neuropsychological assessment
via the Autism Diagnostic Observation Schedule (ADOS;
mean score = 10.82; SD = 3.28). Participants in the ASD
group underwent a comprehensive neurological exam by a
board-certified pediatric neurologist (Alexander Rotenberg,
study M.D.) to confirm the absence of impaired gross or
fine motor function. Participants in the TD group had no
neurological or psychological disorder. Lastly, all participants
were screened following published recommendations endorsed
by the International Federation of Clinical Neurophysiology (see
Table 1 for detailed demographic information).
Neuropsychological Testing
The ADOS (Lord et al., 2000), and the Abbreviated Battery of
Stanford–Binet IV intelligence scale (Thorndike et al., 1986) were
completed for the ASD group. IQ scores were obtained prior to
enrollment only for children with ASD to ensure patients with
intellectual disability or low-functioning ASD were excluded
from enrollment. IQ testing was not performed for TD children,
with the assumption that the IQ of TD children falls within the
normal limits of the general pediatric population.
We limited the enrollment of our ASD participants to HF
children for two reasons: (1) lack of established feasibility of
TMS/cTBS procedures in children with LF ASD; and (2) to
reduce the heterogeneity of our pool of children with ASD,
which are by nature, a heterogeneous population. As such, the
findings reported in this study may be specific only to children
and adolescents with HF-ASD.
Genetic Testing
Saliva samples from participants in the ASD group (n = 8)
were used to assess BDNF Val66Met SNP. The remaining three
participants in the ASD group did not provide consent for DNA
sampling and were thus not included in this subset.
Aliquot (700 µl) extraction of genomic DNA was performed
on saliva samples collected using the Oragene Discover OGR-250
Kit (DNA Genotek Inc., Ottawa, ON, Canada). DNA was
extracted from samples using standard methodology and the
prepIT•L2P reagent (DNA Genotek Inc, 2015). The following
quality control metrics were performed on each sample:
PicoGreen fluorometry for double-strandedDNA quantification,
Nanodrop spectrophotometry as an estimate of sample purity
using A260/A280 ratios and agarose gel electrophoresis for
visualization of DNA integrity.
The rs6265 SNP of the BDNF gene was analyzed using a
TaqMan single-tube genotyping assay, which uses polymerase
chain reaction (PCR) amplification and a pair of fluorescent dye
detectors that target the SNP. One fluorescent dye is attached
to the detector that is a perfect match to the first allele and
a different fluorescent dye is attached to the detector that is a
perfect match to the second allele. During PCR, the polymerase
releases the fluorescent probe into solution where it is detected
using endpoint analysis in an Applied Biosystems Inc. (Foster
City, CA, USA) 7900HT Real-Time instrument. Primers and
probes were also obtained through Applied Biosystems.
Because DNA samples were not available for the TD group,
and a difference in rs6265 SNP prevalence in the ASD and
TD groups could give rise to a difference in cTBS responses
exhibited by the two groups, we estimated the probability
that two hypothetical ASD and TD groups with sample sizes
of 11 and 18, respectively, would have significantly different
BDNF Met−:Met+ ratios. The minor allele frequency of the
rs6265 SNP in the admixed American population in The 1000
Genomes Project Consortium et al. (2015) is approximately
0.153, which translates to 71.79%, 25.88%, and 2.33% for
the prevalence of BDNF Val/Val, Val/Met, and Met/Met
genotypes, respectively. Based on a 0.718:0.282 prevalence ratio
of Met−:Met+ genotypes, we then conducted separate Monte
Carlo simulations (Rubinstein and Kroese, 2016), each with
10,000 iterations, to estimate the probability that either 1, 2,
. . ., or 11 subjects in the ASD group, and either 1, 2, . . ., or
18 subjects in the TD group would have a BDNFMet− genotype.
We then conducted separate Fisher’s exact tests for all possible
combinations of numbers of BDNF Met− subjects in the two
groups and identified the scenarios in which the Met−:Met+
ratio would be significantly different between the two groups. For
each of those scenarios, we then calculated the joint probability of
the two relevant events in the two groups. Finally, we summated
the probabilities of all those mutually exclusive scenarios to
obtain an estimate of the overall probability that two groups
of 11 and 18 subjects randomly sampled from the admixed
American population would be significantly different from one
another in BDNF Met−:Met+ ratio.
Transcranial Magnetic Stimulation
Participants were seated in a comfortable reclining chair with
the right arm and hand in a natural pronated position. They
were instructed to keep their right hand as still and relaxed as
possible throughout the experiment. They were also monitored
for drowsiness and were asked to keep their eyes open during the
TMS application.
All TMS procedures followed the recommended guidelines
endorsed by the International Federation of Clinical
Neurophysiology (Rossi et al., 2009; Rossini et al., 2015).
Single TMS pulses and cTBS were applied to the left M1 at
120% of individual resting motor threshold (RMT) and 80% of
active motor threshold (AMT), respectively, as biphasic pulses
with an anteroposterior–posteroanterior (AP-PA) induced
current direction in the brain. All stimulation was delivered
using a hand-held figure-of-eight coil (outer diameter: 70 mm)
attached to aMagstim Rapid2 Plus1 (Magstim Company Limited,
Whitland, UK) stimulator.












TABLE 1 | Demographics, neuropsychological measures, and medications for individual participants.















AS1 10–15 106 Val/Val Dexmethylphenidate; Sertraline ADHD; Anxiety 11
AS2 10–15 82 Val/Val None None 13
AS3 10–15 100 Val/Met Flouxetine Depression 15
AS4 10–15 100 Val/Met Adderall ADHD; Asthma 7
AS5 10–15 121 Val/Val Clonidine; Melatonin; Sertraline Anxiety; Depression;
Asthma
10
AS6 10–15 100 Val/Met Dexmethylphenidate; Melatonin;
Fluoxetine
Anxiety; Depression 9
AS7 10–15 100 Val/Met Clonidine; Methylphenidate ADHD 10
AS8 15–20 124 Val/Val Melatonin; Methylphenidate ADHD; PTSD; Asthma 16
AS9 10–15 91 - Melatonin None 14
AS10 10–15 100 - Flouxetine; Thyroid tablets Depression;
Hypothyroidism
7










TD1 10–15 None None N/A
TD2 15–20 None None N/A
TD3 10–15 None None N/A
TD4 10–15 None None N/A
TD5 10–15 None None N/A
TD6 10–15 None None N/A
TD7 15–20 None None N/A
TD8 10–15 None None N/A
TD9 10–15 None None N/A
TD10 15–20 None None N/A
TD11 10–15 None None N/A
TD12 10–15 None None N/A
TD13 10–15 None None N/A
TD14 10–15 None None N/A
TD15 10–15 None None N/A
TD16 10–15 None None N/A
TD17 10–15 None None N/A
TD18 15–20 None None N/A
Group averages are presented as means and standard deviations (in parentheses). IQ scores were estimated using the Abbreviated Battery of Stanford-Binet IV intelligence scale. IQ, BDNF, and handedness data were not available
for the TD group. Age range (instead of individual age) and no individual gender information are provided to avoid the possibility of publishing personally identifiable data. Three participants in the ASD group did not complete BDNF
genotyping. ADHD; attention-deficit/hyperactivity disorder; ADOS, Autism Diagnostic Observation Schedule; ASD, autism spectrum disorder; BDNF, brain- derived neurotrophic factor; Met, metionine; PTSD, posttraumatic stress disorder;
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The coil was held tangentially to the participant’s head
surface, with the handle pointing occipitally and positioned
at 45◦ relative to the mid-sagittal axis of the participant’s
head. The optimal spot for the maximal TMS-induced motor
responses of the right first dorsal interosseous (FDI) muscle
(‘‘motor hotspot’’) was localized. A Polaris infrared-optical
tracking system (Northern Digital Inc., Waterloo, ON, Canada)
and a frameless stereotactic neuronavigation system (Brainsight,
Rogue Research Inc., Montreal, QC, Canada) with a brain MRI
template were used to ensure consistent targeting throughout
the experiment. Each participant’s head was registered to the
MRI template using defined cranial landmarks to ensure the coil
position and orientation was consistent with the MRI template
(Ruohonen and Karhu, 2010).
Surface EMG electrodes were placed over the FDI belly
(negative) and the first interphalangeal joint of the second finger
(positive). The ground electrode was placed over the ipsilateral
ulnar styloid process. The TMS system delivered triggered pulses
that synchronized the TMS and EMG systems.
At the start of each TMS session the FDI motor hotspot was
located per patient and individual RMT, defined as the lowest
stimulation intensity necessary to elicit an MEP of ≥50 µV in at
least five of 10 pulses from the relaxed right FDI, was obtained.
To assess pre-cTBS cortico-motor reactivity, three blocks of
30 single TMS pulses in the ASD group, and two blocks of
20 single TMS pulses in the TD group, were applied to M1 with
a 5–10-min inter-block interval, at a random 4–6-s inter-pulse
interval, as done in previous studies (Pechmann et al., 2012;
Gomes-Osman and Field-Fote, 2015; Davila-Pérez et al., 2018).
The different number of single TMS pulses administered
at baseline (90 vs. 40) and in each post-cTBS block (30 vs.
20) in the two groups was due to site-specific approval of
the experimental protocol utilized at each research site. This
difference was unlikely, however, to give rise to differing baseline
MEP amplitude estimates between the two groups, as recent
studies have found applying at least 20 single TMS pulses yields a
reliable estimate of MEP amplitude at a given time point (Chang
et al., 2016; Goldsworthy et al., 2016). In each block, individual
MEPs >2.5 SD from the mean were excluded. The mean (±SD)
number of MEPs in total excluded from all blocks in each subject
was 4.63 (± 1.6) and 2.22 (±1.4) in the ASD and TD groups,
respectively. Thismeans that even in occasional post-cTBS blocks
in the ASD group in which one (or, rarely, two) MEPs were
excluded, there were 19 (or, rarely, 18) pulses remaining in each
block, which has been shown to yield estimates ofMEP amplitude
with excellent internal consistency (Chang et al., 2016). To ensure
hand relaxation was maintained throughout the experiment,
real-time EMG was monitored to ensure the pre-TMS EMG
activity did not exceed∼100µV, which is the amplitude typically
considered to be discernible activity from background EMG
(Stinear and Byblow, 2002; Sartori et al., 2013; Benussi et al.,
2018). Participants were also monitored for drowsiness and
were asked to keep their eyes open for the duration of the
stimulation session.
Baseline MEP amplitude was calculated as the average of the
peak-to-peak amplitude of MEPs in the three blocks. AMT was
then assessed as the lowest intensity that elicited MEPs ≥200 µV
in at least five of 10 pulses with the FDI slightly contracted.
Live EMG was monitored during the AMT assessment to
ensure consistent contraction between ∼100–200 µV. After
a 5-min break, during which participants were instructed to
maintain hand relaxation to control the effects of voluntary
hand movements on cTBS responses (Iezzi et al., 2008), cTBS
was applied as 200 bursts of three pulses at 50 Hz, repeated at
200-ms intervals for 40 s (for a total of 600 pulses). Cortico-
motor reactivity was reassessed at 5, 10, 20, 30, 40, 50, and 60 min
post-cTBS (T5–T60).
Statistical Analyses
Study data were collected and managed using Research
Electronic Data Capture (REDCap) electronic data capture tools
hosted at Beth Israel Deaconess Medical Center (Harris et al.,
2009, 2019). MATLAB R2016b (The MathWorks, Natick, MA,
USA) and Stata 13.1 (StataCorp., College Station, TX, USA) were
used for data analyses and simulations. G∗Power 3.1.9 (Faul et al.,
2007) was used for power and sample-size calculations.
Data from each TMS visit included: (a) RMT and AMT,
expressed as percentage of maximum stimulator output (MSO);
(b) baseline MEP amplitude, calculated as the average of baseline
MEP amplitude in three blocks of 30 single TMS pulses; and
(c) percent change in the average amplitude of 30 MEPs at
T5–T60 relative to baseline (%∆) for each participant.
The Shapiro–Wilk found significant deviations in MEP
amplitudes from the normal distribution. Thus, we first baseline-
corrected each post-cTBS amplitude by dividing it by the
average baseline MEP amplitude in that individual participant.
We then natural log-transformed the baseline-corrected MEP
amplitudes at each post-cTBS time point (∆MEP, Nielsen,
1996a,b; Pasqualetti and Ferreri, 2011) and averaged them
over participants separately for each group. The following
measures were also calculated: maximum suppression of MEPs
during 60 min post-cTBS (∆MEPMax) and the signed area-
under-the-curve (AUC) of ∆MEPs over T5–T10, T5–T20,. . .,
and T5–T60 intervals. To calculate the ∆MEPMax for each
participant, we chose the post-cTBS block (T5–T60) in which
the ∆MEP showed the maximum suppression relative to the
baseline MEP amplitude. Cumulative AUCs of the ∆MEPs
enable numerical integration of cTBS-induced changes in MEP
amplitude over successively larger intervals following cTBS. Such
measures are more robust to the large inter-and intra-individual
variability of MEP amplitudes typically observed at individual
time points post-cTBS (López-Alonso et al., 2014; Vernet et al.,
2014; Vallence et al., 2015; Hordacre et al., 2017; Jannati et al.,
2017, 2019) and can be advantageous in studies with smaller
sample sizes.
Grand-average values for all cTBS measures were calculated
separately for each time point in each group and were compared
between the two groups using independent-samples t-tests.
Similar analyses were conducted for the two small BDNF
subgroups (n = 4 per subgroup) of the ASD group.We conducted
a sample-size analysis based on the preliminary results from the
BDNF subgroups in order to estimate the number of participants
per BDNF subgroup required to detect a significant difference
between the cumulative AUC measures of cTBS aftereffects
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over each interval. Comparisons of proportions were conducted
using Fisher’s exact test. Pearson product-moment correlation
coefficient was used to assess the relationship between∆MEPMax
and age in each group. All analyses were two-tailed, and α and β
levels were set to 0.05 and 0.80, respectively. False discovery rate
(FDR; Benjamini and Yekutieli, 2001) was used to adjust the P-
values for multiple testing.
To obtain a rough estimate on the extent to which our small
sample sizes—combined with the interindividual variability of
MEP changes in response to cTBS—resulted in reduced power,
we conducted a post hoc power calculation for the whole
sample over each post-cTBS interval (but see Hoenig and
Heisey, 2001 for the limited usefulness of this approach) and a
pre-hoc sample-size calculation for the analyses comparing cTBS
responses in the two BDNF subgroups of the ASD group.
To control for the number of pre- and post-cTBS MEPs in
the two groups, we selected a subset of data from the ASD group
such that both the number of baseline MEPs and the number of
MEPs in each post-cTBS block included in the analysis would
be equal in the two groups. Out of the 90 baseline MEPs, we
selected the last 40 MEPs before cTBS to calculate the baseline
MEP amplitude for each subject in the ASD group. We also
selected the 20 MEPs out of 30 MEPs in each post-cTBS block
that centered around the time point of interest (10, 20,. . .,
and 60 min post-cTBS), and then log-transformed the baseline-
corrected MEPs and recalculated the cumulative AUC measures
of cTBS aftereffects for the ASD group. To account for the
occasional MEP amplitudes excluded from each block in the TD
group that was >2.5 SD, we continued to exclude any MEP that
had been excluded from each block in the original, larger ASD
dataset. Finally, we compared those cumulativemeasures of cTBS
aftereffects with the corresponding measures in the TD group, as
described above.
Even though our post-cTBS MEP measures are already
baseline-corrected, it is still possible that a difference in the
absolute baseline MEP amplitude between the two groups
contributes to a difference in cTBS aftereffects. Because, as
reported below, we found a significant difference in baselineMEP
amplitude between the two groups, we set out to create the largest
ASD and TD subgroups that would have comparable baseline
MEP amplitude, and then compared the cTBS aftereffects
between those subgroups.
Because several subjects in the ASD group had comorbid
attention-deficit/hyperactivity disorder (ADHD; Table 1), and
in pediatric ADHD there is impaired GABA-mediated plasticity
as measured by paired-pulse TMS (Dutra et al., 2016; Gilbert
et al., 2019), we repeated the calculation of cumulative AUC
measures of cTBS aftereffects and their comparison between the
ASD and TD groups after excluding the five ASD subjects with a
documented clinical diagnosis of ADHD.
Side-Effect Monitoring
Immediately following the TMS session, a side-effects
questionnaire was completed by the experimenter. Participants
were asked to report whether they experienced any of the
following side effects: headache, neck pain, scalp pain or
irritation, difficulty hearing, thinking or concentrating, change
in mood, or to report any other change or side effect they
experienced. The experimenter also noted whether the
participant experienced a syncopal event or seizure. If the
participant reported any side effects following the stimulation,
the severity and duration were documented.
RESULTS
The ASD and TD groups were comparable in age and sex ratio
(P-values > 0.61). Demographics, neuropsychological measures,
and medications for individual participants are presented in
Table 1.
cTBS Is Safe and Tolerable in Children
All participants tolerated cTBS and single-pulse stimulation
without any serious adverse event. One participant reported
mild scalp irritation (on the forehead underneath the headband
holding the subject tracker of the neuronavigation system),
which was resolved quickly without medication. No other
adverse events were reported.
cTBS Measures of Plasticity Differentiate
Between ASD and TD Children
The difference in cumulative AUC measures of cTBS aftereffects
between the two groups was significant over all the intervals
(PFDR’s < 0.03), indicating greater facilitatory response to cTBS
in the ASD group relative to the TD group. Post-cTBS data from
one participant in the ASD group were not obtained beyond
T10 due to technical difficulties. Grand-average ∆MEPs at
individual post-cTBS time points in the two groups are presented
in Figure 1A. Cumulative AUCs of the ∆MEPs and their
95% confidence intervals (CI) over T5–T10, T5–T20,. . ., and
T5–T60 intervals for the two groups are presented in Figure 1B.
The baseline MEP amplitude (mean ± SD) in the ASD group,
0.37 mV ± 0.27, was significantly smaller than in the TD group,
1.19 mV ± 0.41, t(27) = 5.96, P < 0.001. The largest ASD and
TD subgroups that would have a comparable baseline MEP
amplitude consist of only five participants per subgroup. The
baseline MEP amplitude [mean ± (SD)] in the two resulting
subgroups with n = 5 are comparable: 0.62 mV (±0.17) in
the ASD subgroup and 0.72 mV (±0.17) in the TD subgroup,
t(8) = 0.91, P = 0.39. There is no significant difference in
cumulative AUC ∆MEP measures between the two subgroups
over any of the post-cTBS intervals (P-values > 0.58).
The effect sizes based on the difference in cumulative
AUC measure of cTBS aftereffects between the ASD and TD
groups over T5–T10, T5–T20,. . ., and T5–T60 intervals are
0.85, 0.84, 0.79, 0.70, 0.65, and 0.65, respectively. Assuming
two-tailed, independent-samples t-tests with α = 0.05, the post
hoc power to detect a significant difference between the two
groups are estimated as 57.2%, 56.2%, 51.2%, 42.2%, 37.4%, and
37.4%, respectively.
The Monte Carlo simulations find in a group of 11 subjects,
the estimated probability that either 1, 2,. . ., or 11 subjects would
have a BDNF Met—genotype is < 0.0001, 0.0002, 0.003, 0.012,
0.043, 0.115, 0.198, 0.266, 0.218, 0.113, and 0.027, respectively.
In a group of 18 subjects, the estimated probability that either
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FIGURE 1 | (A) Individual and grand-average change from baseline in MEP amplitude recorded from the right FDI muscle at 5–60 min following cTBS of the left
motor cortex in ASD and TD groups. Error bars represent standard error of the mean. (B) Cumulative AUCs of the ∆MEPs and their 95% CI over T5–T10, T5–T20,
. . ., and T5–T60 intervals for the two groups (the end time-point of each interval is labeled on the abscissa). The cumulative AUC measures were significantly more
positive in the ASD group than in the TD group over all the T5–T10 to T5–T60 intervals (PFDR’s < 0.03). ASD, autism spectrum disorder; AUC, area-under-the-curve;
CI, confidence interval; cTBS, continuous theta-burst stimulation; ∆MEP, natural log-transformed, baseline-corrected amplitude of motor evoked potentials; FDI, first
dorsal interosseous; FDR, false discovery rate; MEP, motor evoked potential; TD, typically developing; Tm–Tn, over m to n minutes following cTBS.
1, 2,. . ., or 18 subjects would have a BDNF Met—genotype
is <0.0001 (for 1–5 such subjects), 0.001, 0.003, 0.010, 0.031,
0.064, 0.120, 0.177, 0.208, 0.185, 0.127, 0.062, 0.019, and 0.002,
respectively. After summating the probability of all scenarios in
which a two-tailed Fisher’s exact test would find a significant
difference in BDNF Met−:Met+ ratio between the ASD and TD
groups, we obtain an overall probability of 0.0426.
After equalizing the number of pre- and post-cTBS MEPs
in the two groups, the cumulative AUC measures of cTBS
aftereffects do not change substantially compared to the
measures obtained with the complete ASD dataset. The mean
(±SD) cumulative AUC of ∆MEP over T5–T10, T5–T20,. . .,
and T5–T60 intervals in this subset of data from the ASD
group is 0.085 (±0.24), 0.18 (±0.45), 0.22 (±0.67), 0.24 (±0.80),
0.20 (± 0.92), and 0.14 (±1.06), respectively. These measures
remain significantly more facilitatory in the ASD group than
in the TD group over all the intervals from T5–T10 to T5–T50
(PFDR’s < 0.047), but not over T5–T60 (PFDR = 0.053).
After excluding the five subjects in the ASD group who
had comorbid ADHD, the cumulative AUC measures of
cTBS aftereffects remain significantly more facilitatory in the
ASD group compared to the TD group over all intervals
(PFDR’s < 0.001).
cTBS Aftereffects Have a Developmental
Trajectory in Children with ASD
∆MEPMax is correlated with age in the ASD group (r = –0.67,
P = 0.025), but not in the TD group (r = –0.12, P = 0.65).
The relationship between age and the maximum cTBS-induced
suppression of MEPs (∆MEPMax) during the first 60 min
post-cTBS in the two groups are illustrated in Figure 2.
BDNF and cTBS Measures of Plasticity in
ASD
The difference in cumulative AUC measures of cTBS aftereffects
between the two BDNF subgroups (Val/Val and Val/Met) of
the ASD group is not statistically significant (P-values > 0.08).
Grand-average ∆MEPs at individual post-cTBS time points in
the twoBDNF subgroups are presented in Figure 3A. Cumulative
AUCs of the∆MEPs and their 95%CI over T0–T10, T0–T20, . . .,
and T0–T60 intervals for the two BDNF subgroups are presented
in Figure 3B.
Based on the results from eight participants with available
BDNF data, the effect size based on the difference in cumulative
AUC measure of cTBS aftereffects over each interval ranges
from 0.78 to 0.87. Assuming a 1:1 ratio between the two
subgroups, the sample size in each BDNF subgroup required
to detect those effect sizes with 80% power ranges from
27 to 22, respectively.
DISCUSSION
We find, considering the caveats and confounders discussed
below, the responses to M1 cTBS can differentiate between
10–16 years old children with HF-ASD and their age-, gender,
and IQ-matched TD children. This is due to more-facilitatory
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FIGURE 2 | The relationship between the maximum cTBS-induced suppression in the natural log-transformed, baseline-corrected MEP amplitude (Max. MEP
suppression) and age in ASD (A) and TD (B) groups. Max. MEP suppression was negatively correlated with age in the ASD group (r = –0.67, P = 0.025), but not in
the TD group (r = –0.12, P = 0.65). Dashed lines represent the slopes of the linear regression fit. ASD, autism spectrum disorder; cTBS, continuous theta-burst
stimulation; MEP, motor evoked potential; TD, typically developing.
FIGURE 3 | (A) Changes in individual and grand-average MEPs recorded from the right FDI muscle at 5–60 min following cTBS of the left primary motor cortex in
BDNF Met− (Val/Val) and Met+ (Val/Met) subgroups of participants with ASD. Error bars represent standard error of the mean. (B) Cumulative AUCs of the ∆MEPs
and their 95% CI over T5–T10, T5–T20, . . ., and T5–T60 intervals for the two BDNF subgroups (the end time-point of each interval is labeled on the abscissa). The
cumulative AUC measures were not significantly different between the two BDNF subgroups over any of the intervals (P-values > 0.18). ASD, autism spectrum
disorder; AUC, area-under-the-curve; BDNF, brain-derived neurotrophic factor; CI, confidence interval; cTBS, continuous theta-burst stimulation; ∆MEP, natural
log-transformed, baseline-corrected amplitude of motor evoked potentials; FDI, first dorsal interosseous; FDR, false discovery rate; MEP, motor evoked potential;
Met, methionine; TD, typically developing; Tm–Tn, over m to n minutes following cTBS; Val, valine.
cTBS aftereffects in MEPs in the ASD group relative to the
TD group. We argue this difference is not likely to be due
to potential confounds such as differences in the number
of pre- and post-cTBS MEPs, BDNF Val66Met SNP, ADHD
comorbidity, or neuroactive medications between the two
groups. Moreover, we report an age-related increase in the
maximum cTBS-induced suppression of MEPs in the ASD
group, but not in the TD group, suggesting a dysmaturity in
LTD-like plasticity in children with ASD. These results indicate
the importance of further investigations of the utility of M1 cTBS
as a potential physiologic biomarker for children and adolescents
with HF-ASD.
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TMS Safety and Tolerability in Children
All participants tolerated the stimulation, and only one
participant reported aminor scalp irritation that resolved quickly
without medication. The present study adds to the growing
literature documenting the safety and tolerability of rTMS in
children and in individuals with ASD (Garvey and Gilbert, 2004;
Frye et al., 2008; Croarkin et al., 2011; Oberman et al., 2012, 2014,
2016; Wu et al., 2012; Rajapakse and Kirton, 2013; Hong et al.,
2015; Pedapati et al., 2015; Hameed et al., 2017).
cTBS as a Biomarker for Children and
Adolescents With ASD
We find that the pattern of cTBS aftereffects during the first
60 min post-cTBS successfully differentiates between the ASD
and TD groups. Namely, the ASD group shows significantlymore
facilitatory responses to cTBS than the TD group throughout the
assessed post-cTBS interval (Figure 1). Notably, this pattern of
results is not driven by one or two particular post-cTBS time
points, which can be prone to the large inter- and intra-individual
variability in cTBS responses observed in adults (López-Alonso
et al., 2014; Vernet et al., 2014; Vallence et al., 2015; Hordacre
et al., 2017; Jannati et al., 2017, 2019).
The finding that the ASD group exhibits a distinct pattern of
cTBS from their TD counterparts indicates the potential utility
of M1 cTBS as a biomarker for children and adolescents with
HF-ASD. Moreover, considering the involvement of GABAergic
synaptic transmission in cTBS aftereffects (Stagg et al., 2009;
Trippe et al., 2009), the facilitatory (rather than inhibitory)
responses to cTBS in the ASD group further supports the
notion of GABAergic dysfunction in ASD (LeBlanc and Fagiolini,
2011; Ben-Ari et al., 2012; Coghlan et al., 2012). The effect of
GABAergic transmission during typical development shifts from
excitatory to inhibitory through sequential activation of chloride
(Cl−) cotransporters NKCC1 and KCC2 and via age-dependent
reduction of intracellular Cl− concentration (Yamada et al., 2004;
Ben-Ari et al., 2007). Rodent ASD models indicate a delayed
shift of GABA activity from excitatory to inhibitory, which can
be restored behaviorally and electrophysiologically by in utero
administration of the NKCC1 inhibitor bumetanide (Tyzio et al.,
2014). Similarly, bumetanide treatment may mitigate core ASD
symptoms in children and adolescents (Lemonnier et al., 2017).
We thus suggest that cTBS measures of M1 plasticity in ASD can
be used to assess baseline cortico-motor reactivity, probe-target
engagement, and monitor therapeutic response to experimental
pharmacotherapy (e.g., bumetanide; Lemonnier et al., 2017)
and, potentially, future rTMS treatments for ASD (Cole et al.,
2019). Moreover, differential cTBS responses within the pediatric
ASD population can form the physiologic basis for a clinical
endophenotype that improves classification and understanding
of the pathophysiology of ASD.
The more-facilitatory response to cTBS in the ASD group
relative to the TD group is consistent with the results of previous
studies that have found impaired LTP-like changes in MEPs in
individuals with ASD by paired associative stimulation (PAS;
Jung et al., 2013) and iTBS (Oberman et al., 2012; Pedapati
et al., 2016). Given that cTBS also likely engages GABAergic
mechanisms, our results are also consistent with related findings
that employ other TMS-derived biomarkers. For instance,
GABAAergic activity, as measured by short-interval intracortical
cortical inhibition (SICI), was associated with a delay in language
acquisition in adults with ASD (Enticott et al., 2013).
Present and Anticipated Confounders
Although the post-cTBS measures reported in the present study
are already adjusted for baselineMEP amplitude at the individual
level, it is possible that a difference in the baselineMEP amplitude
at the group level contributes to the observed differences in
cTBS aftereffects between ASD and TD groups. The finding
that the baseline MEP amplitude is significantly smaller in
the ASD group than in the TD group can be either due to
chance because of the small sample sizes or because of a real
difference in input-output characteristics of MEPs in the two
groups (Goetz et al., 2014). Because the largest ASD and TD
subgroups with a comparable baseline MEP amplitude consist
of only five participants, the present sample does not allow for
a robust assessment of the effect of group-level baseline MEP
amplitude on cTBS aftereffects in the two groups. Larger samples
in future studies aimed at comparing rTMS responses between
ASD and control populations can address this limitation by
ensuring comparable baseline MEP amplitudes at the group level
between the two groups.
Our analysis controlling for the number of baseline and
post-cTBS MEPs shows that the differences in cumulative
measures of cTBS aftereffects, at least from T5–T10 to T5–T50,
are not due to differences in the number of baseline MEPs (90 vs.
40) or the number of MEPs in each post-cTBS block (30 vs. 20)
between the ASD and TD groups.
One issue that needs to be considered in comparing cTBS
responses between the ASD and TD groups is the potential effects
of neuroactive medications on cTBS responses. It is plausible that
at least some of those medications influence the pattern of cTBS
aftereffects in ASD participants and thus the difference between
the two groups. There is, however, considerable variability in
the type of those medications received by our ASD participants,
which makes it unlikely that all or a majority of them have
a similar effect on the plasticity mechanisms indexed by cTBS
aftereffects. To maintain the external validity of the findings of
studies aimed at developing biomarkers or therapeutics for the
ASD population, it is necessary to include patients who are under
treatment by neuroactive medications prescribed for common
comorbidities such as depression, anxiety, and ADHD.
Another issue in comparing cTBS responses between the
ASD and TD groups is the possibility that there is a significant
difference in BDNF Met−:Met+ ratio between the two groups.
Such difference can give rise to an observed difference in cTBS
responses between the two groups that are not necessarily
associated with an ASD diagnosis but with the composition of
BDNF genotypes in the two groups. Our simulations, however,
do not find such a possibility to be very likely in the present
study. We find, assuming random sampling from the admixed
American population, there is a ∼4.3% chance that two groups
of 11 and 18 subjects are significantly different from one another
in the BDNF Met−:Met+ ratio.
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Potential confound due to psychiatric comorbidities in the
ASD group is another factor that can mediate the difference
in cTBS responses between the two groups. One common
comorbidity in ASD is ADHD (Craig et al., 2015), in which
abnormal GABA-mediated plasticity measured by paired-pulse
TMS has been observed (Dutra et al., 2016; Gilbert et al.,
2019). After excluding five subjects in the ASD group with
documented ADHD comorbidity, we still find significantly
greater cumulative facilitatory aftereffects of cTBS in the ASD-
without-ADHD subgroup than in the TD group across all
post-cTBS intervals. These results show that the observed
differences between the whole ASD group and the TD group
cannot not be due to the effects of ADHD comorbidity on
cTBS responses. In general, nonetheless, in studies comparing
plasticity responses of ASD and control populations, the
potential effects of common psychiatric comorbidities such as
depression, anxiety, and ADHD on TMS measures of plasticity,
should be considered.
Interestingly, the overall pattern of cTBS responses in the ASD
group in the present study is not necessarily what one would
expect based on previous results. Namely, a previous cTBS study
from our group (Oberman et al., 2014) found only one-third of
children and adolescents with ASD showed facilitatory responses
to cTBS. This difference in results can be due to several factors:
(1) The large inter-individual variability in response to cTBS
among healthy adults is now well-established (Hamada et al.,
2013; Goldsworthy et al., 2014; López-Alonso et al., 2014;
Nettekoven et al., 2015; Vallence et al., 2015; Hordacre et al.,
2017; Jannati et al., 2017). A similar degree of variability in
cTBS responses in TD children and among clinical pediatric
populations such as children with ASD is reasonable to
expect. By mere virtue of random sampling from a large
spectrum of responses, such variability can give rise to
seemingly inconsistent results in small sample sizes that may
not capture the entire gamut of cTBS responses in healthy and
clinical populations. In fact, our post hoc power calculation
for the whole sample indicates that the present study is
underpowered, especially beyond the T5–T20 interval. Larger
sample sizes would perhaps have resulted in more-robust
differences, and/or over longer intervals, between the two
groups. We thus anticipate that this power analysis will enable
the design of future studies with larger sample sizes that are
required to confirm and extend the present results.
(2) The difference in the proportion of participants with BDNF
Val/Met genotype, which has been shown to influence cTBS
and other rTMS measures of neuroplasticity (Cheeran et al.,
2008; Antal et al., 2010; Lee et al., 2013; Chang et al., 2014; Di
Lazzaro et al., 2015; Fried et al., 2017; Jannati et al., 2017, 2019)
may have contributed to the different results.
(3) Differences in other demographic, neuropsychological, and
genetic factors as well as neuroactive medications received by
the participants in the ASD group could have given rise to the
different patterns of cTBS response in the two studies.
These potential confounds underscore the need for
replication of present findings in future cTBS studies with
large samples of children and adolescents with ASD in order
to overcome, or control for, some of these factors. Another
important reason for replicating the present findings is to assess
the test-retest reliability of M1 cTBS aftereffects in both HF-ASD
and TD children. This is underscored by the recent findings in
healthy adults that indicate low-to-moderate reliability of most
cTBS aftereffects (Jannati et al., 2019).
Regarding potential selection and outcome biases in
recruiting the participants in the TD group, it should be
noted that because the TD subjects were recruited as part of an
unrelated study—and not for the purpose of comparing their
cTBS responses with those of ASD children—such biases did not
play a role in recruiting the TD subjects.
Developmental Trajectory of cTBS
Responses in ASD
Consistent with the previously reported age-related increase
in the duration of cTBS-induced modulation in children and
adolescents with ASD (Oberman et al., 2014), we find an
age-related increase in the maximum cTBS-induced suppression
of MEP during 60 min post-cTBS in the ASD group, but not
in the TD group. Namely, older participants with ASD tend to
exhibit greater cTBS-induced LTD-like plasticity than younger
participants with ASD, whereas there is no such developmental
trajectory in the TD group (at least in the age range of 11–16).
Caution should be exercised in interpreting these correlations,
however, because of the short dynamic range of age in the
two groups. Assuming these results are confirmed in larger
studies in the future and over wider age ranges, they suggest
a dysmaturity in LTD-like plasticity as measured by cTBS in
children with ASD, perhaps arising from a dysfunction in
the shift of GABAergic activity from excitatory to inhibitory.
Since GABAA-receptor activity is involved in generating the
cTBS aftereffects, such dysfunction would cause the ASD
participants to achieve greater inhibitory cTBS responses as
they grow older. In contrast, because the GABAergic shift
presumably occurs earlier in TD children, they may achieve
greater cTBS-induced inhibition at a younger age and then
plateau at older ages. These results hint at the utility of cTBS
measures of plasticity as longitudinal tools for monitoring
the development of cortical plasticity and/or gradual response
to potential treatments among children and adolescents with
ASD. Because the slope of such developmental trajectory
is likely to vary across individuals with ASD, a substantial
number of subjects at any given age may be necessary to
obtain robust ‘‘growth curves’’ for cortical plasticity in pediatric
ASD populations.
BDNF Polymorphism and cTBS
Aftereffects in ASD
The role of BDNF Val66Met SNP in influencing rTMS plasticity
measures in adults has been investigated in several studies
(Cheeran et al., 2008; Antal et al., 2010; Lee et al., 2013;
Chang et al., 2014; Di Lazzaro et al., 2015; Fried et al., 2017;
Jannati et al., 2017, 2019). BDNF Met carrier status is known
to be associated with impaired N-Methyl-D-aspartate-(NMDA)-
dependent LTD (Woo et al., 2005), aberrant GABAergic synaptic
transmission (Abidin et al., 2008), reduced cTBS-induced
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inhibition of MEPs (Chung et al., 2016), and, in some cases,
paradoxical cTBS-induced facilitation of MEPs (Gentner et al.,
2008; Goldsworthy et al., 2012; Hellriegel et al., 2012; Brownjohn
et al., 2014; Jannati et al., 2017, 2019). In contrast with these
results, the BDNF Met+ children with ASD in the present study
exhibit a numerically more-inhibitory response than the BDNF
Met− children at all individual post-cTBS time points, even
though the difference between two subgroups is not statistically
significant. Because of the small sample sizes, it is difficult to infer
whether the seemingly opposite effect of BDNFMet carrier status
on cTBS response in childrenwith ASD compared to adults is due
to: (1) sampling error arising from small sample sizes; or (2) a
dysfunction in GABAergic shift that causes the BDNF SNP to
have an opposite influence on cTBS aftereffects in children with
ASD compared to healthy individuals.
CONCLUSION
Considering the discussed limitations and potential confounders,
cTBS-derived metrics may enable practical and safe physiologic
biomarkers in pediatric ASD. Given that such measures can
be applied repeatedly to individuals, our data also point to
prospects for probing developmentally regulated features of
cortical plasticity in ASD and perhaps other neurodevelopmental
disorders. Because of its high tolerability by patients with
ASD, cTBS offers an opportunity to study the mechanisms and
alterations of neural plasticity in the ASD population. These
proof-of-principle findings in the motor cortex can be followed
in future studies through extra motor stimulation in TMS-EEG
or similar protocols.
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